Clinical Trials Browser

Phase 1 × Plasmacytoma × 90 days × Clear all

NCT03031730 2026-02-10

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Phase 1 Terminated

35 enrolled 10 charts

Multiple Myeloma, Plasmacytoma